nature.com

Heterozygous variants disrupting the interaction of Erf with activated ERK1/2 cause microcephaly, developmental delay,…

Abstract

Heterozygous deleterious null alleles and specific missense variants in the DNA-binding domain of the ETS2 repressor factor (ERF) cause craniosynostosis, while the recurrent p.(Tyr89Cys) missense variant is associated with Chitayat syndrome. Exome and whole transcriptome sequencing revealed the ERF de novo in-frame indel c.911_913del selectively removing the serine of the FSF motif, which interacts with the extracellular signal-regulated kinases (ERKs), in a 10-year-old girl with microcephaly, multiple congenital joint dislocations, generalized joint hypermobility, and Pierre-Robin sequence. Three additional cases with developmental delay variably associated with microcephaly, Pierre-Robin sequence and minor skeletal anomalies were detected carrying heterozygous de novo non-truncating alleles (two with c.911_913del and one with the missense c.907 T > A change) in the same FSF motif. Protein affinity maps, co-immunoprecipitation experiments and subcellular distribution showed that both the variants impair the interaction between ERF and activated ERK1/2 and increase ERF nuclear localization, affecting ERF repressor activity that may lead to developmental defects. Our work expands the phenotypic spectrum of ERF-related disorders to a pleiotropic condition with microcephaly, developmental delay and skeletal anomalies, that we termed MIDES syndrome, and adds to the understanding of the relevance of the ERF-ERK interaction in human development and disease.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Change institution

Buy or subscribe

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Learn more

Buy this article

Purchase on SpringerLink

Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Fig. 1: Clinical and molecular data of Individual 1.

Fig. 2: ERF-Phe303Ile and ERF-Ser304del variants alter the ability of ERF to interact with the ERK1/2 kinases.

Fig. 3: ERF-Phe303Ile and ERF-Ser304del variants strongly decrease interaction with activated ERK1/2 and increase nuclear accumulation of ERF.

Data availability

The authors declare that all data supporting the findings of this study are available within the article and its supplementary material files, or from the corresponding author upon reasonable request.

Code availability

The underlying code for this study may be made available to qualified researchers on reasonable request from the corresponding author.

References

Athanasiou M, Blair DG, Mavrothalassitis G. ERF, an ETS-related transcriptional repressor, can induce erythroid differentiation. Anticancer Res. 2003;23:2143–53.

CASPubMedGoogle Scholar

Peraki I, Palis J, Mavrothalassitis G. The Ets2 Repressor Factor (Erf) is required for effective primitive and definitive hematopoiesis. Mol Cell Biol. 2017;37:e00183-17.

Papadaki C, Alexiou M, Cecena G, Verykokakis M, Bilitou A, Cross JC, et al. Transcriptional repressor erf determines extraembryonic ectoderm differentiation. Mol Cell Biol. 2007;27:5201–13.

ArticleCASPubMedPubMed CentralGoogle Scholar

Vorgia E, Zaragkoulias A, Peraki I, Mavrothalassitis G. Suppression of Fgf2 by ETS2 repressor factor (ERF) is required for chorionic trophoblast differentiation. Mol Reprod Dev. 2017;84:286–95.

ArticleCASPubMedGoogle Scholar

Glass GE, O’Hara J, Canham N, Cilliers D, Dunaway D, Fenwick AL, et al. ERF-related craniosynostosis: The phenotypic and developmental profile of a new craniosynostosis syndrome. Am J Med Genet A. 2019;179:615–27.

ArticleCASPubMedPubMed CentralGoogle Scholar

Twigg SR, Vorgia E, McGowan SJ, Peraki I, Fenwick AL, Sharma VP, et al. Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis. Nat Genet. 2013;45:308–13.

ArticleCASPubMedPubMed CentralGoogle Scholar

Sgouras DN, Athanasiou MA, Beal GJ Jr, Fisher RJ, Blair DG, Mavrothalassitis GJ. ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. EMBO J. 1995;14:4781–93.

ArticleCASPubMedPubMed CentralGoogle Scholar

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017;546:671–5.

ArticleCASPubMedPubMed CentralGoogle Scholar

Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, et al. Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov. 2017;7:973–83.

ArticleCASPubMedPubMed CentralGoogle Scholar

Athanasiou M, LeGallic L, Watson DK, Blair DG, Mavrothalassitis G. Suppression of the Ewing’s sarcoma phenotype by FLI1/ERF repressor hybrids. Cancer Gene Ther. 2000;7:1188–95.

ArticleCASPubMedGoogle Scholar

Ogura K, Elkrief A, Bowman AS, Koche RP, de Stanchina E, Benayed R, et al. Prospective clinical genomic profiling of ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance. JCO Precis Oncol. 2022;6:e2200048.

ArticlePubMedPubMed CentralGoogle Scholar

Lackner A, Muller M, Gamperl M, Stoeva D, Langmann O, Papuchova H, et al. The Fgf/Erf/NCoR1/2 repressive axis controls trophoblast cell fate. Nat Commun. 2023;14:2559.

ArticleCASPubMedPubMed CentralGoogle Scholar

Vega-Sendino M, Olbrich T, Tillo D, Tran AD, Domingo CN, Franco M, et al. The ETS transcription factor ERF controls the exit from the naive pluripotent state in a MAPK-dependent manner. Sci Adv. 2021;7:eabg8306.

ArticleCASPubMedPubMed CentralGoogle Scholar

Polychronopoulos S, Verykokakis M, Yazicioglu MN, Sakarellos-Daitsiotis M, Cobb MH, Mavrothalassitis G. The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs. J Biol Chem. 2006;281:25601–11.

ArticleCASPubMedGoogle Scholar

Chaudhry A, Sabatini P, Han L, Ray PN, Forrest C, Bowdin S. Heterozygous mutations in ERF cause syndromic craniosynostosis with multiple suture involvement. Am J Med Genet A. 2015;167A:2544–7.

ArticlePubMedGoogle Scholar

Korberg I, Nowinski D, Bondeson ML, Melin M, Kolby L, Stattin EL. A progressive and complex clinical course in two family members with ERF-related craniosynostosis: a case report. BMC Med Genet. 2020;21:90.

ArticlePubMedPubMed CentralGoogle Scholar

Lee E, Le T, Zhu Y, Elakis G, Turner A, Lo W, et al. A craniosynostosis massively parallel sequencing panel study in 309 Australian and New Zealand patients: findings and recommendations. Genet Med. 2018;20:1061–8.

ArticleCASPubMedGoogle Scholar

Moddemann MK, Kieslich M, Koenig R. Intrafamilial variability in six family members with ERF-related craniosynostosis syndrome type 4. Am J Med Genet A. 2022;188:2969–75.

ArticleCASPubMedGoogle Scholar

Dentici ML, Niceta M, Lepri FR, Mancini C, Priolo M, Bonnard AA, et al. Loss-of-function variants in ERF are associated with a Noonan syndrome-like phenotype with or without craniosynostosis. Eur J Hum Genet. 2024;32:954–963.

Yamada M, Funato M, Kondo G, Suzuki H, Uehara T, Takenouchi T, et al. Noonan syndrome-like phenotype in a patient with heterozygous ERF truncating variant. Congenit Anom (Kyoto). 2021;61:226–30.

ArticleCASPubMedGoogle Scholar

Calpena E, McGowan SJ, Blanco Kelly F, Boudry-Labis E, Dieux-Coeslier A, Harrison R, et al. Dissection of contiguous gene effects for deletions around ERF on chromosome 19. Hum Mutat. 2021;42:811–7.

ArticleCASPubMedGoogle Scholar

Singh R, Cohen ASA, Poulton C, Hjortshoj TD, Akahira-Azuma M, Mendiratta G, et al. Deletion of ERF and CIC causes abnormal skull morphology and global developmental delay. Cold Spring Harb Mol Case Stud. 2021;7:a005991.

Balasubramanian M, Lord H, Levesque S, Guturu H, Thuriot F, Sillon G, et al. Chitayat syndrome: hyperphalangism, characteristic facies, hallux valgus and bronchomalacia results from a recurrent c.266A>G p.(Tyr89Cys) variant in the ERF gene. J Med Genet 2017;54:157–65.

ArticleCASPubMedGoogle Scholar

Suter AA, Santos-Simarro F, Toerring PM, Abad Perez A, Ramos-Mejia R, Heath KE, et al. Variable pulmonary manifestations in Chitayat syndrome: Six additional affected individuals. Am J Med Genet A. 2020;182:2068–76.

ArticleCASPubMedGoogle Scholar

Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010;29:2147–60.

ArticleCASPubMedPubMed CentralGoogle Scholar

Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586:757–62.

ArticleCASPubMedPubMed CentralGoogle Scholar

Wang T, Kim CN, Bakken TE, Gillentine MA, Henning B, Mao Y, et al. Integrated gene analyses of de novo variants from 46,612 trios with autism and developmental disorders. Proc Natl Acad Sci USA. 2022;119:e2203491119.

ArticleCASPubMedPubMed CentralGoogle Scholar

Alexa A, Sok P, Gross F, Albert K, Kobori E, Poti AL, et al. A non-catalytic herpesviral protein reconfigures ERK-RSK signaling by targeting kinase docking systems in the host. Nat Commun. 2022;13:472.

ArticleCASPubMedPubMed CentralGoogle Scholar

Ravindranath PA, Forli S, Goodsell DS, Olson AJ, Sanner MF. AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput Biol. 2015;11:e1004586.

ArticlePubMedPubMed CentralGoogle Scholar

Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292:195–202.

ArticleCASPubMedGoogle Scholar

Zhang Y, Sanner MF. AutoDock CrankPep: combining folding and docking to predict protein-peptide complexes. Bioinformatics. 2019;35:5121–7.

ArticleCASPubMedPubMed CentralGoogle Scholar

Le Gallic L, Sgouras D, Beal G Jr, Mavrothalassitis G. Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation. Mol Cell Biol. 1999;19:4121–33.

ArticlePubMedPubMed CentralGoogle Scholar

Le Gallic L, Virgilio L, Cohen P, Biteau B, Mavrothalassitis G. ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression. Mol Cell Biol. 2004;24:1206–18.

ArticlePubMedPubMed CentralGoogle Scholar

Turner TN, Wilfert AB, Bakken TE, Bernier RA, Pepper MR, Zhang Z, et al. Sex-based analysis of De Novo variants in neurodevelopmental disorders. Am J Hum Genet. 2019;105:1274–85.

ArticleCASPubMedPubMed CentralGoogle Scholar

Treen N, Chavarria E, Weaver CJ, Brangwynne CP, Levine M. An FGF timer for zygotic genome activation. Genes Dev. 2023;37:80–5.

ArticleCASPubMedPubMed CentralGoogle Scholar

Vogiatzi A, Baltsavia I, Dialynas E, Theodorou V, Zhou Y, Deligianni E, et al. Erf affects commitment and differentiation of osteoprogenitor cells in cranial sutures via the retinoic acid pathway. Mol Cell Biol. 2021;41:e0014921.

ArticlePubMedGoogle Scholar

Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29:1463–86.

ArticleCASPubMedPubMed CentralGoogle Scholar

Dash S, Trainor PA. The development, patterning and evolution of neural crest cell differentiation into cartilage and bone. Bone. 2020;137:115409.

ArticleCASPubMedGoogle Scholar

Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5:181.

ArticleCASPubMedPubMed CentralGoogle Scholar

Download references

Acknowledgements

MC is member of the ReCONNET ERN (European Reference Network for rare and complex musculoskeletal diseases) and ERN SKIN (European Reference Network for rare and complex skin diseases).

Funding

This work was supported by the Ricerca Corrente 2022–2024 to MC, Ricerca Finalizzata (project code: RF_2021_12373524), Italian Ministry of Health to MC and DC; European Regional Development Fund of the European Union and Greek national funds through the National Recovery and Resilience Program (project code: TAEDR-0535850) to GM; Fondazione Telethon Core Grant, Armenise-Harvard Foundation Career Development Award, European Research Council (grant agreement 759154, CellKarma) and Piano Operativo Salute Traiettoria 3, “Genomed,” Italian Ministry of Health to DC. The funder played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.

Author information

Authors and Affiliations

Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, Viale Cappuccini snc, 71013, San Giovanni Rotondo, Italy

Lucia Micale, Carmela Fusco, Riccardo Pracella, Grazia Nardella, Maria Pia Leone & Marco Castori

IMBB, FORTH, 71003, Heraklion, Crete, Greece

Aikaterini Vourlia, Lydia Xenou & George Mavrothalassitis

Medical School, University of Crete, 71003, Heraklion, Crete, Greece

Aikaterini Vourlia, Dimitrios-Christoforos Karagiannis & George Mavrothalassitis

Armenise/Harvard Laboratory of Integrative Genomics, Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078, Pozzuoli, Italy

Lorenzo Vaccaro, Antonio Gramazio & Davide Cacchiarelli

Department of Translational Medicine, University of Naples “Federico II”, Naples, Italy

Lorenzo Vaccaro, Antonio Gramazio & Davide Cacchiarelli

Rare Diseases and Medical Genetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

Maria Lisa Dentici

Translational Cytogenetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

Chiara Aiello & Antonio Novelli

Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA

Yang Sui & Evan E. Eichler

Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA

Evan E. Eichler

Genomics and Experimental Medicine Program, Scuola Superiore Meridionale, Naples, Italy

Davide Cacchiarelli

Authors

Lucia Micale

View author publications

You can also search for this author in PubMedGoogle Scholar

2. Aikaterini Vourlia

View author publications

You can also search for this author in PubMedGoogle Scholar

3. Carmela Fusco

View author publications

You can also search for this author in PubMedGoogle Scholar

4. Riccardo Pracella

View author publications

You can also search for this author in PubMedGoogle Scholar

5. Dimitrios-Christoforos Karagiannis

View author publications

You can also search for this author in PubMedGoogle Scholar

6. Grazia Nardella

View author publications

You can also search for this author in PubMedGoogle Scholar

7. Lorenzo Vaccaro

View author publications

You can also search for this author in PubMedGoogle Scholar

8. Maria Pia Leone

View author publications

You can also search for this author in PubMedGoogle Scholar

9. Antonio Gramazio

View author publications

You can also search for this author in PubMedGoogle Scholar

10. Maria Lisa Dentici

View author publications

You can also search for this author in PubMedGoogle Scholar

11. Chiara Aiello

View author publications

You can also search for this author in PubMedGoogle Scholar

12. Antonio Novelli

View author publications

You can also search for this author in PubMedGoogle Scholar

13. Lydia Xenou

View author publications

You can also search for this author in PubMedGoogle Scholar

14. Yang Sui

View author publications

You can also search for this author in PubMedGoogle Scholar

15. Evan E. Eichler

View author publications

You can also search for this author in PubMedGoogle Scholar

16. Davide Cacchiarelli

View author publications

You can also search for this author in PubMedGoogle Scholar

17. George Mavrothalassitis

View author publications

You can also search for this author in PubMedGoogle Scholar

18. Marco Castori

View author publications

You can also search for this author in PubMedGoogle Scholar

Contributions

MC, GM, and LM contributed to the study conception and design. Material preparation, data collection and interpretation were performed by MC, DC, GM, and LM. Funtional analysis were performed by CF, DCK, LM, GN, AV, and LX. ES data were provided by CA, EEE, MLD, MPL, LM, AN, and YS. RNA sequencing was carried out by AG, LV, and DC. In silico analysis was performed by RP. The first draft of the manuscript was written by MC, LM, and GM. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Lucia Micale or George Mavrothalassitis.

Ethics declarations

Competing interests

All authors declare that there is no conflict of interest concerning this work. DC is founder, shareholder, and consultant of NEGEDIA S.r.l.

Ethics approval

This study is in accordance with the 1984 Helsinki declaration and subsequent revisions, and received IRB approval at Fondazione IRCCS-Casa Sollievo della Sofferenza (approval no. 2023/45/CE). All patients provided written informed consent for participation in this study and publication of molecular and clinical data.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Methods_revised-clean

Table_S1

Table_S2

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Micale, L., Vourlia, A., Fusco, C. et al. Heterozygous variants disrupting the interaction of ERF with activated ERK1/2 cause microcephaly, developmental delay, and skeletal anomalies. Eur J Hum Genet (2024). https://doi.org/10.1038/s41431-024-01721-9

Download citation

Received:18 June 2024

Revised:20 August 2024

Accepted:17 October 2024

Published:12 December 2024

DOI:https://doi.org/10.1038/s41431-024-01721-9

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative

Read full news in source page